Found 20 articles for: "clascoterone"
Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis
April 2024 | Volume 23 | Issue 4 | Original Article | 216 | Copyright © April 2024
Background: Multiple treatment options exist for the management of moderate-to-severe acne. However, the comparative effectiveness (efficacy/safety) of moderate-to-severe acne tr...
Read MoreBenefit of Topical Combination Therapy for Acne: Analyzing Effect Size Using Number Needed to Treat
February 2024 | Volume 23 | Issue 2 | Original Article | 42 | Copyright © February 2024
Background: Topical acne trials often are confounded by high vehicle response rates and differing outcome measures, making it difficult to compare treatments. Number needed to tr...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreHormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
August 2023 | Volume 22 | Issue 8 | Original Article | 785 | Copyright © August 2023
Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition characterized by recurrent abscesses, nodules, and sinus tracts. Hormones are thought to play an impor...
Read MoreIndividual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne
June 2023 | Volume 22 | Issue 6 | Supplement Individual Articles | SF350992s7 | Copyright © June 2023
Acne is a prevalent chronic inflammatory disease that can cause severe psychiatric effects and physical scarring of the skin. Historically, although systemic antiandrogen acne medications have be...
Read MoreFULL SUPPLEMENT: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne
June 2023 | Volume 22 | Issue 6 | Department | SF350992s5 | Copyright © June 2023
Acne is a prevalent chronic inflammatory disease that can cause severe psychiatric effects and physical scarring of the skin. Historically, although systemic antiandrogen acne medications have be...
Read MoreThe Many Faces of Pediatric Acne: A Practical Algorithm for Treatment, Maintenance Therapy, and Skincare Recommendations for Pediatric Acne Patients
June 2023 | Volume 22 | Issue 6 | Original Article | 539 | Copyright © June 2023
Background: Pediatric acne is a common, complex, multifactorial inflammatory skin disease with various expressions in childhood that can be categorized by age, severity, and pube...
Read MoreUnmet Needs in the Management of Acne Vulgaris: A Consensus Statement
June 2023 | Volume 22 | Issue 6 | Original Article | 582 | Copyright © June 2023
Acne vulgaris is the most common skin condition in the US, affecting up to 50 million Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment were developed to provide r...
Read MoreEfficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023
Background: Two randomized phase 3 studies evaluated efficacy and safety of 1% clascoterone cream, a topical androgen receptor inhibitor, in patients aged ≥9 years with modera...
Read MoreSUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene
December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446185 | Copyright © December 2022
Acne vulgaris of the trunk carries with it a major psychosocial impact and an unmet need for adequate management. Approximately 50% of patients with facial acne also exhibit involvement of the back, c...
Read MoreSupplement Individual Article: Racial Ethnic Variations in Acne: A Practical Algorithm for Treatment and Maintenance, Including Skincare Recommendations for Skin of Color Patients With Acne
November 2022 | Volume 21 | Issue 11 | Supplement Individual Articles | SF3446083 | Copyright © November 2022
Background: Racial/ethnic differences in the clinical presentation, sequelae, and desired treatment outcomes for acne have been reported. Post-inflammatory hyperpigmentation (PIH) frequently occurs in...
Read MoreHormonal Therapies in the Management of Acne Vulgaris
June 2022 | Volume 21 | Issue 6 | Original Article | 618 | Copyright © June 2022
Acne vulgaris is a multifactorial chronic disorder of the pilosebaceous unit. Established treatments include topical retinoids, antibiotics in mild cases, and oral antibiotics and isotretinoin in mode...
Read MoreNever Give Up! Continued Progress in Development of Topical Therapies for Acne Is a Good Thing
June 2022 | Volume 21 | Issue 6 | Editorials | 571 | Copyright © June 2022
In July 2022, I will reach the milestone of practicing dermatology for 36 years, with 30 years of experience also devoted to clinical research. My background in pharmacy before attending medical schoo...
Read MoreARTICLE: Androgens, Androgen Receptors, and the Skin: From the Laboratory to the Clinic With Emphasis on Clinical and Therapeutic Implications
March 2020 | Volume 19 | Issue 3 | Supplement Individual Articles | 30 | Copyright © March 2020
The effects of androgens on human skin include growth and differentiation of sebaceous glands, terminal hair growth, epidermal barrier function, wound healing, and modification of the cutaneous microb...
Read MoreARTICLE: Game Changer in Acne Treatment
March 2020 | Volume 19 | Issue 3 | Supplement Individual Articles | 28 | Copyright © March 2020
Of the four primary pathogenic factors that drive acne vulgaris—androgen excess, increased sebum production, faulty keratinization, and overgrowth of C. acnes—androgen excess has been the ...
Read MoreA Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne
June 2019 | Volume 18 | Issue 6 | Original Article | 570 | Copyright © June 2019
Androgens play a key role in acne pathogenesis in both males and females. Read More
Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study
June 2019 | Volume 18 | Issue 6 | Original Article | 563 | Copyright © June 2019
Clascoterone (cortexolone 17α-propionate, CB-03-01) 1% cream, a topical, androgen receptor (AR) inhibitor under...
Read MoreCortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro
May 2019 | Volume 18 | Issue 5 | Original Article | 412 | Copyright © May 2019
Cortexolone 17α-propionate (clascoterone) is a novel topical androgen antagonist that is being analyzed for its ability to treat acne. The pathogenesis of acne is attributed to multiple factors,...
Read MoreCortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro
February 2019 | Volume 18 | Issue 2 | Original Article | 197 | Copyright © February 2019
Cortexolone 17α-propionate (clascoterone) is a novel androgen antagonist that is currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA). W...
Read MoreMedia and other results for: "clascoterone"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
